knowledge -WSS

knowledge

author：explore 2025-09-28 23:11:47 - browse：5654

Photograph of Bill Cassidy. -- health policy coverage from STAT — Sen. Bill Cassidy (R-La.) Kevin Dietsch/Getty Images

WASHINGTON — With Novo Nordisk’s Wegovy and Ozempic hitting blockbuster sales and a new rival approved this week, everyone in Washington is thinking about how to manage the crashing wave of weight loss drug costs.

The explosive national demand for weight management therapies and diabetes drugs like Ozempic — all of which are indicated for indefinite use — has become central in an ongoing policy debate over high drug costs and controversial tactics to manage them, including President Biden’s plan to let the government negotiate directly with pharmaceutical companies. Seventy percent of Americans could qualify for these medicines.

Sen. Bill Cassidy (R-La.), the highest-ranking Republican on the Senate’s health policy committee, has vehemently opposed the negotiation plan, arguing it reduces incentives to develop new therapies and may not actually reduce patients’ costs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Hubble vs. James Webb telescope images: See the difference

leisure time

WSS

Australia’s approach to dialysis celebrates life

FDA panel gives mixed vote on blood pressure devices

How to make AI work for medicine

UpToDate has a racism problem: Dr. Stanley Goldfarb

CDC advisory panel says seniors 'may' get RSV vaccine

A letter from the executive editor: The 2023 STATUS List

knowledge

knowledge

entertainment

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The wait for US passports is creating travel purgatory and snarling summer plans

Medical records are filled with copy

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

Medicare details structure of new drug price negotiation program

The biotech scorecard for Q3: 15 stock

The high cost of giving birth even with insurance

How to make AI work for medicine

23andMe had bad news about my health. I wish a person had delivered it

AstraZeneca bets AAV gene therapy will still deliver the goods

hotspot

'Screen and refer' systems are hurting patients

FDA panel gives mixed vote on blood pressure devices

Prescription digital therapeutics are key to pharma’s future

Psilocybin's anti

'Screen and refer' systems are hurting patients

Why more medical students aren't specializing in primary care

entertainment

leisure time

hotspot

focus